Cellectis S.A is a biotechnology business based in the US. Cellectis S-A shares (CLLS) are listed on the NASDAQ and all prices are listed in US Dollars. Cellectis S-A employs 272 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Cellectis S-A
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CLLS – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Cellectis S-A stock price (NASDAQ: CLLS)Use our graph to track the performance of CLLS stocks over time.
Cellectis S-A shares at a glance
|Latest market close||$15.67|
|52-week range||$13.13 - $34.71|
|50-day moving average||$14.92|
|200-day moving average||$20.09|
|Wall St. target price||$34.78|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.24|
Buy Cellectis S-A shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Cellectis S-A stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Cellectis S-A price performance over time
|1 week (2021-07-19)||N/A|
|1 month (2021-06-30)||1.29%|
|3 months (2021-04-30)||-15.80%|
|6 months (2021-01-26)||N/A|
|1 year (2020-07-26)||N/A|
|2 years (2019-07-26)||N/A|
|3 years (2018-07-26)||N/A|
|5 years (2016-07-26)||N/A|
Cellectis S-A financials
|Revenue TTM||$58.5 million|
|Gross profit TTM||$46.2 million|
|Return on assets TTM||-16.35%|
|Return on equity TTM||-39.2%|
|Market capitalisation||$596.1 million|
TTM: trailing 12 months
Shorting Cellectis S-A shares
There are currently 1.3 million Cellectis S-A shares held short by investors – that's known as Cellectis S-A's "short interest". This figure is 6.3% up from 1.2 million last month.
There are a few different ways that this level of interest in shorting Cellectis S-A shares can be evaluated.
Cellectis S-A's "short interest ratio" (SIR)
Cellectis S-A's "short interest ratio" (SIR) is the quantity of Cellectis S-A shares currently shorted divided by the average quantity of Cellectis S-A shares traded daily (recently around 263894.76987448). Cellectis S-A's SIR currently stands at 4.78. In other words for every 100,000 Cellectis S-A shares traded daily on the market, roughly 4780 shares are currently held short.
However Cellectis S-A's short interest can also be evaluated against the total number of Cellectis S-A shares, or, against the total number of tradable Cellectis S-A shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cellectis S-A's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Cellectis S-A shares in existence, roughly 30 shares are currently held short) or 0.0435% of the tradable shares (for every 100,000 tradable Cellectis S-A shares, roughly 44 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cellectis S-A.
Find out more about how you can short Cellectis S-A stock.
Cellectis S-A share dividends
We're not expecting Cellectis S-A to pay a dividend over the next 12 months.
Cellectis S-A share price volatility
Over the last 12 months, Cellectis S-A's shares have ranged in value from as little as $13.13 up to $34.71. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cellectis S-A's is 2.1524. This would suggest that Cellectis S-A's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Cellectis S-A overview
Cellectis S. A. , a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat.
Cellectis S-A in the news
Cellectis organise une conférence téléphonique pour présenter ses résultats financiers du deuxième trimestre 2021 le vendredi 6 août à 14h00 CET
Cellectis to Hold Second Quarter 2021 Earnings Call on Friday, August 6, 2021 at 8AM EDT
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Frequently asked questionsWhat percentage of Cellectis S-A is owned by institutions?
Currently 43.076% of Cellectis S-A shares are held by institutions. How many people work for Cellectis S-A?
Latest data suggests 272 work at Cellectis S-A. When does the fiscal year end for Cellectis S-A?
Cellectis S-A's fiscal year ends in December. Where is Cellectis S-A based?
Cellectis S-A's address is: 8, rue de la Croix Jarry, Paris, France, 75013 What is Cellectis S-A's ISIN number?
Cellectis S-A's international securities identification number is: US15117K1034 What is Cellectis S-A's CUSIP number?
Cellectis S-A's Committee on Uniform Securities Identification Procedures number is: 15117K103
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert